During the gene therapy trial, they slowed the disease’s progress in 75 percent of cases, allowing patients to live potentially decades longer with a better quality of life.

The condition rapidly kills brain cells and is usually fatal within two decades of symptoms revealing themselves, affecting an estimated 75,000 people in the UK alone.












Follow us on social media